Brief: Euroapi Expects Between 8% And 11% Decrease In 2024 Net Sales VS 2023

Euroapi SA

26/06/2024 16:50

June 26 (Reuters) - Euroapi SA  EAPI.PA :
    * EUROAPI IS MOVING AHEAD WITH ITS FOCUS-27 PLAN
    * 75 TO 80 MEUR ANNUAL RUN-RATE INCREMENTAL CORE EBITDA
TARGETED
BY END OF 2027
    * AGREEMENT WITH SANOFI ON A 200 M€ INVESTMENT THROUGH A
PERPETUAL
SUBORDINATED HYBRID BOND
    * BRINDISI SITE EXPECTED TO PROGRESSIVELY RESUME SHIPMENTS
AND
PRODUCTION DURING Q3 2024
    * UPON THE COMPLETION OF THE ONGOING DISCUSSIONS TO AMEND
AND
EXTEND THE CURRENT REVOLVING CREDIT FACILITY
    * 350 TO 400 MEUR CAPEX PLAN, INCLUDING INCREASED CAPACITIES
FOR
LARGE MOLECULES, VITAMIN B12, PROSTAGLANDINS, AND OPIATES
    * DIVESTMENT OF HAVERHILL AND BRINDISI MANUFACTURING SITES
PLANNED
BEFORE END OF 2027
    * RESTRUCTURING COSTS ESTIMATED IN RANGE OF 110-120 MEUR
BETWEEN
2024 AND 20271F
    * BETWEEN 8% AND 11% DECREASE IN 2024 NET SALES COMPARED TO
2023
ON A COMPARABLE BASIS

Source text for Eikon:  ID:nGNE99rk85 
Further company coverage:  EAPI.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))